Related Experiment Video

Updated: Sep 30, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Rapid Lorlatinib Response in Lung Adenocarcinoma With a Novel Y Chromosome Intergenic ALK Fusion: A Case Report

Jin-Ming Chen1, Yi-Fan Kang1, Yue-Can Zeng1

  • 1Department of Radiation Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.

Clinical Lung Cancer
|September 28, 2026
PubMed

Abstract:

CLINICAL PRACTICE POINTS.

Keywords:
Intergenic ALK fusionNon-canonical fusionNon-small cell lung cancerPrecision oncologyTyrosine kinase inhibitor

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Experiment Videos

Last Updated: Sep 30, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

Articles linked to this work by shared authors, journal, and citation graph.

TLS-related immune organization and regional IRF4 expression in pretreatment biopsies of advanced lung adenocarcinoma.

Lung cancer (Amsterdam, Netherlands)·2026

An optimized EfficientNetB7 deep learning model for lung cancer tissue pathology image recognition.

Frontiers in oncology·2026

Broadband InP-based 2-μm semiconductor optical amplifier enabling hybrid integrated external-cavity lasers.

Optics letters·2026

Edge-sharing RuO2 single layer for stable and low overpotential acidic water electrolysis.

Nature nanotechnology·2026

BMI threshold associates with increased 30-day complications after total thyroidectomy surgery.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026

Hemiarthroplasty as management for solitary metastasis of the proximal humerus: a retrospective study.

Annals of medicine·2026

Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD.

Clinical lung cancer·2026

Racial Disparities in Thymic Epithelial Tumors: Insights From a Multiracial Urban Cohort.

Clinical lung cancer·2026

A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer: JCOG2510 (PRIME-CRT).

Clinical lung cancer·2026

Assessment of Prognostic Value of CEACAM5 Expression Using Archival Tissue and Real-World Evidence of Metastatic Patients with NSCLC in United States.

Clinical lung cancer·2026

Low Baseline Absolute Neutrophil Count and Chemotherapy Safety in African American Patients with Advanced Lung Cancer: A Retrospective Cohort Study.

Clinical lung cancer·2026

MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and/or Amplification: A Global Real-World Study.

Clinical lung cancer·2026

Application of natural products combined with plant-derived extracellular vesicles in cancer therapy.

Experimental biology and medicine (Maywood, N.J.)·2026

Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis.

Frontiers in pharmacology·2026

Tumor-antigen-specific polyclonal antibodies suppress tumor growth and metastasis in heterogeneous solid tumors.

Frontiers in oncology·2026

Cannabidiol preserves astrocyte viability and attenuates injury-induced glial stress responses across zebra finch song control nuclei.

Frontiers in pharmacology·2026

Mutations in Chromatin Regulator Genes Associate With TMB and Immunotherapy Response in Melanoma.

Pigment cell & melanoma research·2026

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl-2 and Mcl-1 blockade in preclinical glioblastoma models.

FEBS open bio·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us